BioSpace News Archive

Signature comedy fundraiser helps to fund stomach cancer research.

AllerPops were created by Dr. Cliff Han, a biologist at the Los Alamos National Lab.

Phase 1b/2a study will evaluate the safety and efficacy of the combination of Hyleukin-7™ (NT-I7) and KEYTRUDA® (pembrolizumab) in patients with Relapsed/Refractory Advanced Solid Tumors

Phase 2 study will Examine the Effect of Mavrilimumab on the Clinical Profile of Yescarta

PET study of BTRX-335140 confirms KOR target engagement in the brain

Bel Air Award Program Honors the Achievement

NeuroTracker was selected among 750 emerging tech companies in the digital health space.

The Alliance for Regenerative Medicine, the international advocacy organization representing the cell and gene therapy and broader regenerative medicine sector, announced its 2020 Cell & Gene Therapies State of the Industry briefing will take place January 13, 2020 in San Francisco, held in conjunction with Biotech Showcase™ 2020.

EXMceuticals Inc. (CSE: EXM) (FSE: A2PAW2) (the “Company” or “EXM”), a producer of cannabis extractions and refined ingredients for the pharmaceutical, nutraceutical, therapeutical and cosmetic industries, is very pleased to provide a corporate update following a series of announcements in the last few months

Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical company specializing in the research and development of cannabinoid therapeutics, announced today the filing of a new U.S. Patent for its proprietary and novel CBD-like molecules to treat radiation dermatitis (RD) and other skin disorders.